|
1
|
Jones PA and Baylin SB: The Epigenomics of
Cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Macaluso M, Paggi MG and Giordano A:
Genetic and epigenetic alterations as hallmarks of the intricate
road to cancer. Oncogene. 22:6472–6478. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Madhukar G and Subbarao N: Current and
future therapeutic targets: A review on treating head and neck
squamous cell carcinoma. Curr Cancer Drug Targets. 21:386–400.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gingerich MA, Smith JD, Michmerhuizen NL,
Ludwig M, Devenport S, Matovina C, Brenner C and Chinn SB:
Comprehensive review of genetic factors contributing to head and
neck squamous cell carcinoma development in low-risk,
nontraditional patients. Head Neck. 40:943–954. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hunter KD, Parkinson EK and Harrison PR:
Profiling early head and neck cancer. Nat Rev Cancer. 5:127–135.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Conley BA: Treatment of advanced head and
neck cancer: What lessons have we learned? J Clin Oncol.
24:1023–1025. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dubey P, Gupta R, Mishra A, Kumar V,
Bhadauria S and Bhatt MLB: Evaluation of correlation between CD44,
radiotherapy response, and survival rate in patients with advanced
stage of head and neck squamous cell carcinoma (HNSCC). Cancer Med.
11:1937–1947. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Demurtas S, Ingargiola R, Orlandi E and
Locati LD: How can we address the challenge of distant metastases
in HNSCC prognosis? Expert Rev Anticancer Ther. 22:781–783. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sayed SI, Dwivedi RC, Katna R, Garg A,
Pathak KA, Nutting CM, Rhys-Evans P, Harrington KJ and Kazi R:
Implications of understanding cancer stem cell (CSC) biology in
head and neck squamous cell cancer. Oral Oncol. 47:237–243. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Trapasso S and Allegra E: Role of CD44 as
a marker of cancer stem cells in head and neck cancer. Biologics.
6:379–383. 2012.PubMed/NCBI
|
|
14
|
Joshua B, Kaplan MJ, Doweck I, Pai R,
Weissman IL, Prince ME and Ailles LE: Frequency of cells expressing
CD44, a head and neck cancer stem cell marker: Correlation with
tumor aggressiveness. Head Neck. 34:42–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chikamatsu K, Takahashi G, Sakakura K,
Ferrone S and Masuyama K: Immunoregulatory properties of CD44+
cancer stem-like cells in squamous cell carcinoma of the head and
neck. Head Neck. 33:208–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kokko LL, Hurme S, Maula SM, Alanen K,
Grénman R, Kinnunen I and Ventelä S: Significance of site-specific
prognosis of cancer stem cell marker CD44 in head and neck
squamous-cell carcinoma. Oral Oncol. 47:510–516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spring FA, Dalchau R, Daniels GL,
Mallinson G, Judson PA, Parsons SF, Fabre JW and Anstee DJ: The Ina
and Inb blood group antigens are located on a glycoprotein of
80,000 MW (the CDw44 glycoprotein) whose expression is influenced
by the In (Lu) gene. Immunology. 64:37–43. 1988.PubMed/NCBI
|
|
18
|
Nakamura H, Suenaga N, Taniwaki K, Matsuki
H, Yonezawa K, Fujii M, Okada Y and Seiki M: Constitutive and
induced CD44 shedding by ADAM-like proteases and membrane-type 1
matrix metalloproteinase. Cancer Res. 64:876–882. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Misra S, Heldin P, Hascall VC, Karamanos
NK, Skandalis SS, Markwald RR and Ghatak S: Hyaluronan-CD44
interactions as potential targets for cancer therapy. FEBS J.
278:1429–1443. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kannagi R, Cochran NA, Ishigami F,
Hakomori S, Andrews PW, Knowles BB and Solter D: Stage-specific
embryonic antigens (SSEA-3 and −4) are epitopes of a unique
globo-series ganglioside isolated from human teratocarcinoma cells.
EMBO J. 2:2355–2361. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pornsuriyasak P and Demchenko AV:
Synthesis of cancer-associated glycoantigens: Stage-specific
embryonic antigen 3 (SSEA-3). Carbohydr Res. 341:1458–1466. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuroda Y, Kitada M, Wakao S, Nishikawa K,
Tanimura Y, Makinoshima H, Goda M, Akashi H, Inutsuka A, Niwa A, et
al: Unique multipotent cells in adult human mesenchymal cell
populations. Proc Natl Acad Sci USA. 107:8639–8643. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kobayashi Y, Kitahara H, Hirai M, Tanaka
A, Jokaji R, Kobayashi K, Bou-Gharios G, Nakamura H and Kawashiri
S: Selectively high efficacy of eribulin against high-grade
invasive recurrent and/or metastatic squamous cell carcinoma of the
head and neck. Oncol Lett. 17:5064–5072. 2019.PubMed/NCBI
|
|
24
|
Kobayashi JI, Hirohashi Y, Torigoe T,
Michifuri Y, Yamamoto T, Tamura Y, Kamiguchi K, Miyazaki A,
Yamaguchi A, Hariu H, et al: Clonal diversity of cytotoxic T
lymphocytes that recognize autologous oral squamous cell carcinoma.
Hum Immunol. 70:89–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Suzuki Y, Haraguchi N, Takahashi H, Uemura
M, Nishimura J, Hata T, Takemasa I, Mizushima T, Ishii H, Doki Y,
et al: SSEA-3 as a novel amplifying cancer cell surface marker in
colorectal cancers. Int J Oncol. 42:161–167. 2013.PubMed/NCBI
|
|
28
|
Yang Z, Liu J, Liu H, Qiu M, Liu Q, Zheng
L, Pang M, Quan F and Zhang Y: Isolation and characterization of
SSEA3(+) stem cells derived from goat skin fibroblasts. Cell
Reprogram. 15:195–205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suila H, Pitkänen V, Hirvonen T, Heiskanen
A, Anderson H, Laitinen A, Natunen S, Miller-Podraza H, Satomaa T,
Natunen J, et al: Are globoseries glycosphingolipids SSEA-3 and −4
markers for stem cells derived from human umbilical cord blood? J
Mol Cell Biol. 3:99–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leng Z, Sun D, Huang Z, Tadmori I, Chiang
N, Kethidi N, Sabra A, Kushida Y, Fu YS, Dezawa M, et al:
Quantitative analysis of SSEA3+ cells from human umbilical cord
after magnetic sorting. Cell Transplant. 28:907–923. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang WW, Lee CH, Lee P, Lin J, Hsu CW,
Hung JT, Lin JJ, Yu JC, Shao LE, Yu J, et al: Expression of Globo H
and SSEA3 in breast cancer stem cells and the involvement of
fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad
Sci USA. 105:11667–11672. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abal M, Andreu J and Barasoain I: Taxanes:
Microtubule and centrosome targets, and cell cycle dependent
mechanisms of action. Curr Cancer Drug Targets. 3:193–203. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hennenfent KL and Govindan R: Novel
formulations of taxanes: A review. Old wine in a new bottle? Ann
Oncol. 17:735–749. 2006.PubMed/NCBI
|
|
34
|
Schrijvers D and Vermorken JB: Taxanes in
the treatment of head and neck cancer. Curr Opin Oncol. 17:218–224.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rowinsky EK: The development and clinical
utility of the taxane class of antimicrotubule chemotherapy agents.
Annu Rev Med. 48:353–374. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ishii H, Iwatsuki M, Ieta K, Ohta D,
Haraguchi N, Mimori K and Mori M: Cancer stem cells and
chemoradiation resistance. Cancer Sci. 99:1871–1877. 2008.
View Article : Google Scholar : PubMed/NCBI
|
